A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. METHODS: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), we determined the maximum tolerated dose (MTD) of afatini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: O’Brien, Mary E. R., Sarker, Debashis, Bhosle, Jaishree, Thillai, Kiruthikah, Yap, Timothy A., Uttenreuther-Fischer, Martina, Pemberton, Karine, Jin, Xidong, Wiebe, Sabrina, de Bono, Johann, Spicer, James
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182763/
https://ncbi.nlm.nih.gov/pubmed/30088048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3661-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados